Clinical Trials | Healthy Adults At Risk of Alzheimer’s Disease May be Eligible for a New Clinical Trial
RETAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer’s Disease
The Department of Neurology’s Memory Division seeks adults ages 55 to 75 with normal cognitive aging for a research study and a reliable study partner who knows the participant well. The purpose of the study is to test the safety, tolerability, and effectiveness of an investigational medicine for slowing the onset of Alzheimer’s Disease. This study involves taking an experimental vaccine/placebo, blood draws, cognitive testing, brain imaging. Participants have a 50/50 chance of receiving the investigational medication. The study will involve about 7 visits annually over the course of 4 years. Visits will last from 30 minutes to 3 hours. Study-related exams, tests and experimental medication provided at no cost.